Desvenlafaxine Tablet, Extended Release
Product Images NDC 46708-541

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 46708-541). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30's Bottle Pack (Desvenlafaxine 100mg)

Label for Desvenlafaxine Extended-Release Tablets 100 mg by Alembic Pharmaceuticals Limited. The label includes storage instructions, a NDC number 46708-541-30, dosage form as extended-release tablets, package count of 30 tablets, and manufacturer details in Gujarat, India. It also contains dispensing instructions and a barcode.*

FDA Label Image

30's Bottle Pack (Desvenlafaxine 25mg)

Desvenlafaxine Extended-Release Tablet 25 mg film-coated tablets from Alembic Pharmaceuticals Limited. The label indicates each tablet contains 38 mg desvenlafaxine succinate equivalent to 25 mg desvenlafaxine. Packaging includes 30 tablets with instructions for pharmacist to dispense a medication guide. Storage conditions and usage directions are noted, including the labeler address in Gujarat, India.*

FDA Label Image

30's Bottle Pack (Desvenlafaxine 50mg)

Label for Desvenlafaxine Extended-Release Tablets 50 mg by Alembic Pharmaceuticals Limited. The film-coated, extended-release tablets contain desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. The package contains 30 tablets, with storage instructions at 20° to 25°C (68° to 77°F). Includes dispensing guidance and manufacturer details from Gujarat, India.*

FDA Label Image

Figure 1 (Desvenlafaxine Figure1)

A pharmacokinetic chart depicting geometric mean ratios (90% confidence intervals) of Cmax and AUC for Desvenlafaxine extended release tablets, analyzed across different renal and hepatic impairment levels, as well as population groups by gender and age. The x-axis shows change relative to reference from 0.5 to 3.5. Categories include mild, moderate, severe renal and hepatic impairment, ESRD, females, and age groups 65-75 years and above 75 years.*

FDA Label Image

Figure 2 (Desvenlafaxine Figure2)

A pharmacokinetic chart showing the geometric mean ratio with 90% confidence intervals for Cmax and AUC changes due to CYP3A4 inhibitor ketoconazole. The x-axis represents change relative to reference, ranging from 0.5 to 2. Cmax shows a slight increase near 1.08, and AUC a larger increase around 1.43, each indicated with corresponding data points and confidence intervals.*

FDA Label Image

Figure 3 (Desvenlafaxine Figure3)

A forest plot chart titled 'Geometric mean ratio (90% CI)' showing the pharmacokinetic interaction of Desvenlafaxine with various drugs. The X-axis represents change relative to reference, ranging from 0.5 to 2.5. The chart compares Cmax and AUC values for Desipramine, Midazolam, Tamoxifen, and Aripiprazole at different Desvenlafaxine doses, including 50 mg, 100 mg, and 400 mg, with plotted points and confidence intervals indicating the magnitude and variability of drug interaction effects.*

FDA Label Image

Figure 4 (Desvenlafaxine Image4)

A line graph showing the estimated proportion of patients with relapse (%) over time in days from randomization. It compares Desvenlafaxine Extended-Release Tablets 50 mg with a placebo, illustrating trends in relapse rates during the study period.*

FDA Label Image

Figure 5 (Desvenlafaxine Image5)

A Kaplan-Meier curve chart showing the estimated proportion of patients with relapse (%) over time in days from randomization, comparing Desvenlafaxine Extended-Release Tablets to Placebo. The solid line represents Desvenlafaxine, and the dashed line represents Placebo, illustrating differences in relapse rates during the study period up to about 180 days.*

FDA Label Image

Structure (Desvenlafaxine Structure1)

Chemical structure of Desvenlafaxine Succinate, a human prescription drug with oral extended-release tablet dosage forms available in strengths of 25 mg, 50 mg, and 100 mg. The structure shows the molecular arrangement including phenyl, cyclohexanol, and succinate groups along with associated water molecules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.